PreveCeutical Medical Inc.

PreveCeutical Medical Inc. is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

Recent News

  • PreveCeutical - Australian Patent Granted for Disulfide Bond Containing Compounds

    Vancouver, British Columbia--(Newsfile Corp. - January 25, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the grant of Australian patent no. 2018305726, titled "Disulfide bond containing compounds and uses thereof," on January 5, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has licensed it exclusively to PreveCeutical. The Australian patent protects the disulfide linker platform technology, which is used in peptides...

    2023-01-25 7:00 AM EST
  • PreveCeutical - Background IP, US Patent Granted Disulfide Bond Containing Compounds

    Vancouver, British Columbia--(Newsfile Corp. - January 23, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that US patent no. 11,566,044, titled 'Disulfide bond containing compounds and uses thereof', will be granted on January 31, 2023. The patent is owned by the University of Queensland (UQ) in Australia, and UniQuest (UQ's commercialization company) has granted PreveCeutical exclusive rights to the platform technology. The US patent protects the disulfide linker platform...

    2023-01-23 7:00 AM EST
  • PreveCeutical - Dynorphin Peptides (Painkiller) and Uses Thereof Patent Update and Officer Update

    Vancouver, British Columbia--(Newsfile Corp. - January 17, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to peptide analogues of dynorphin and their use in pain management (International Patent Application No. PCT/AU2021/050707, Peptides and Uses) and is taking the International patent application forward in the US, Europe, Canada and Australia.The US patent application (USSN 18/003,768) has been filed with amended claims,...

    2023-01-17 7:00 AM EST
  • PreveCeutical Enters into License Option Agreement with Endosane Pharmaceuticals

    Vancouver, British Columbia--(Newsfile Corp. - January 12, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a License Option Agreement with Endosane Pharmaceuticals GmbH ("Endosane"), a subsidiary of Sanity Group, dated January 10, 2023, pursuant to which Endosane has been granted an option to license the sol-gel technology for the delivery of cannabinoid products on an exclusive basis (the "Option Agreement").The purpose of the Option Agreement is...

    2023-01-12 6:00 AM EST
  • PreveCeutical Signs Intercompany Sol-Gel License Agreement

    Vancouver, British Columbia--(Newsfile Corp. - January 9, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that it has entered into a license agreement with its subsidiary PreveCeutical (Australia) Pty Ltd. (the "Subsidiary" or "PAPL") for the exclusive rights to the Sol-Gel intellectual property and technology for the delivery of cannabinoids ("Sol-Gel License").PAPL has an exclusive license agreement with UniQuest Pty Ltd, the commercialization company of The University of Queensland ("UniQuest"), giving...

    2023-01-09 7:00 AM EST
  • PreveCeutical Files Application for D-amino Acid Peptides

    Vancouver, British Columbia--(Newsfile Corp. - November 21, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a PCT (Patent Cooperation Treaty) application number PCT/IB2022/06117 on November 18, 2022, entitled "Peptides and Uses Thereof", with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer.This patent application is made to protect the peptides comprising D-amino acids identified in the...

    2022-11-21 8:00 AM EST
  • PreveCeutical Announces Conversion of Debt

    Vancouver, British Columbia--(Newsfile Corp. - November 11, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into an assignment agreement with a certain arm's length assignee (the "Assignee").Per the assignment agreement, the Assignee acquired all of Stephen Van Deventer and Kimberly Van Deventer's rights, title, interests and obligations in and under a convertible credit facility agreement dated effective July 18, 2022, as to the aggregate principal amount of $240,000 and the...

    2022-11-11 7:30 PM EST
  • Appointment of Kathleen Rokita to PreveCeutical's Board of Directors

    Vancouver, British Columbia--(Newsfile Corp. - October 20, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") , announces the appointment of Ms. Kathleen Rokita ("Kathy") to the Company's board of directors (the "Board").Kathy is a CPA and Principal of Somerset CPA's P.C. She is a finance, operations, and strategy-focused executive with extensive experience with large medical groups. Her experience includes financial performance improvement, business development, operational process improvement, information reporting/analytics, treasury management, budgeting and payor...

    2022-10-20 8:00 AM EDT